Respiratory Viral Vaccines
Icosavax Inc. focuses on vaccine research for respiratory syncytial virus and human metapneumovirus, with clinical interest in preventing lower respiratory tract disease in older adults.
- RSV prevention
- hMPV prevention
- VLP vaccine development
The company’s clinical activity is centered on adult immunization, particularly in populations aged 60 years and older.
Lower Respiratory Tract Disease
Its research addresses RSV lower respiratory tract disease and hMPV lower respiratory tract disease, reflecting a therapeutic interest in viral illnesses that can cause significant respiratory morbidity.
- Confirmed respiratory infection
- Seasonal protection
- Older adult respiratory health
This area of work is directed toward reducing clinically important respiratory outcomes in high-risk adult populations.
Immunogenicity and Safety
The sponsor also evaluates immunogenicity and safety for its respiratory vaccine program, with attention to immune response generation in older adults.
- Immune response
- Vaccine tolerability
- Placebo-controlled evaluation
These studies support clinical assessment of protection against targeted viral respiratory disease.
